Riluzole

Biohaven Ltd. has withdrawn its European marketing application for Dazluma, an experimental treatment for spinocerebellar ataxia, after the EMA expressed concerns about its effectiveness and classification as a new active substance.

BrainStorm Cell Therapeutics has submitted an IND amendment to the FDA for NurOwn, its autologous mesenchymal stem cell therapy for ALS, setting the stage for a pivotal Phase 3b clinical trial.

A late-stage ALS patient treated with Trethera's investigational drug TRE-515 under FDA's Expanded Access program showed disease stabilization over three months, with improvements in vital capacity and functional rating scales.

Phase 2 clinical trial demonstrates IFB-088 (icerguastat) meets primary safety endpoint and shows significant reduction in disease progression for bulbar-onset ALS patients.

NeuroSense Therapeutics has entered a binding term sheet with a leading global pharmaceutical company for PrimeC development, securing upfront payment and Phase 3 trial funding.